Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

About NXL104

NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (penicillins, cephalosporins, carbopenems) mediated by beta-lactamase enzymes.

NXL104 is a significant advance, as it is able to inhibit a broader range of beta-lactamases than currently marketed inhibitors. Its spectrum includes class A (including ESBL and KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae and Pseudomonas.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... - Broadened Diagnostic Criteria and Growing ... despite Patent Expirations ... Therapeutics to 2020 - Broadened Diagnostic ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... April 15, 2011 HeartWare International, Inc. (NASDAQ: ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced the presentation of updated data ... study, ADVANCE, showing 180-day survival, using Kaplan-Meier analysis, ...
... Md., April 15, 2011 The U.S. Food and ... device to treat adults with glioblastoma multiforme (GBM) that ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the brain tissue. According to the National Cancer Institute, ...
Cached Medicine Technology:HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5FDA Approves New Medical Device for Form of Brain Cancer 2FDA Approves New Medical Device for Form of Brain Cancer 3
(Date:8/28/2014)... Career Step, an online provider of ... video designed to help students and career seekers explore ... field. The video details what medical coders and billers ... and the education requirements for entering this field. , ... overlooked when people are considering a career in healthcare,” ...
(Date:8/28/2014)... (PRWEB) August 29, 2014 VPS ... a physical server computer into many servers, each ... running on someone’s own dedicated computer. Top10BestSEOHosting.com has ... announces that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ), Bluehost and ... suppliers in 2014. , The IT manager of ...
(Date:8/28/2014)... AltMed , a fully ... to the development and production of medical cannabis, ... location in Sarasota County. , "Sarasota County ... commitment to attracting new industry and the job ... Wright, President and CEO of AltMed. "Their responsive ...
(Date:8/28/2014)... Fifty percent of adults who seek medical ... percent of Americans claim to have fatigue that is ... Fatigue is the most common yet overlooked cause of ... symptoms. Tasks that were once a breeze are now ... cause irritation, experiencing weight gain around the middle area ...
(Date:8/28/2014)... August 28, 2014 When David Gergen, ... long-time friend of Mark Brnovich, was asked to publicly ... nomination for the Attorney General seat in the State ... gathered the support of Cardinal Hall of Fame wide ... Derek Kennard and Mark Walczak. Green, Kennard and Walczak ...
Breaking Medicine News(10 mins):Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Top10BestSEOHosting.com Announces The Best Three VPS Hosting Suppliers 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Peoria AlignLife Clinics Focus on Community Education 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3
... paying fatally to keep thin, the Indian fashion fraternity says ... sari or the lehenga and the// models must keep healthy. ... say, and, are away from harm's way. ,The ... to anorexia, an eating disorder, and 22-year-old Luisel Ramos because ...
... prevent breast cancer and also help those who are suffering ... surveyed 15,000 women and found that those who indulged in ... no family history of breast cancer may be 23 percent ... exercise at all. ,Another study showed that a ...
... success in a Brazilian soap opera has inspired the production ... ,The doll will be based on "Paginas da ... Joana Mocarzel. ,In the soap, the five-year-old Clarinha ... Mocarzel's charisma combined with Brazilians' craze for soaps to make ...
... a million children in India suffering from serious hearing problems ... prohibitive cost of such surgery is keeping them away, health ... India suffer some kind of hearing problems and about a ... surgery. But the high cost of the device is proving ...
... plan to distribute 250,000 city-branded condoms as part of ... of HIV// and other sexually transmitted infections, the Washington ... yellow package is printed in English and Spanish and ... to stop HIV in D.C.' The first batch of ...
... at the University of Illinois at Urbana-Champaign have developed ... with sensitivity that rivals the performance of much more ... a fast, on-site test for assessing uranium contamination in ... Yi Lu, a chemistry professor at Illinois and senior ...
Cached Medicine News:Health News:Indian Models are a Healthy Lot 2Health News:Need for Cost-effective Hearing Implants 2Health News:Free Condoms Distribution to Prevent HIV in Washington 2Health News:DNA-based Detection of Heavy Metals 2
... Our Buffered Wright-Giemsa Stain is ... contains the fixative, buffer, and ... staining of blood smears. It ... bottle for ease of use ...
... Giemsa stain is an excellent classical ... blood smears and bone marrow. Erythrocytes ... exhibiting a very light, pale pink. ... cytoplasm stains the classical "ground glass" ...
Albumin (BCP). Storage temp: 15 - 30 C. Linearity: 0.5 - 8.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 250 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Medicine Products: